UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.69 Million Position in AtriCure, Inc. $ATRC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 76.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 131,853 shares of the medical device company’s stock after selling 423,261 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.26% of AtriCure worth $3,689,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in AtriCure during the second quarter valued at approximately $125,198,000. Bank of America Corp DE acquired a new stake in shares of AtriCure in the 2nd quarter valued at $24,465,000. Grandeur Peak Global Advisors LLC acquired a new stake in shares of AtriCure in the 2nd quarter valued at $16,435,000. Osterweis Capital Management Inc. bought a new position in shares of AtriCure in the 2nd quarter valued at $14,028,000. Finally, Marshall Wace LLP raised its holdings in shares of AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after buying an additional 354,281 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the topic of several research analyst reports. UBS Group reduced their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Needham & Company LLC boosted their target price on AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Piper Sandler increased their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Insider Activity at AtriCure

In other news, insider Justin Noznesky sold 6,182 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 61,379 shares of company stock valued at $2,557,552. Corporate insiders own 4.00% of the company’s stock.

AtriCure Trading Down 1.3%

NASDAQ ATRC opened at $53.03 on Thursday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $55.72. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 252.54 and a beta of 1.26. The business’s fifty day moving average is $41.54 and its 200 day moving average is $33.26.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.